AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
U.S. FDA accepts NDA for Merck’s doravirine islatravir
ByAinvest
Thursday, Jul 10, 2025 6:46 am ET1min read
U.S. FDA accepts NDA for Merck’s doravirine islatravir
The U.S. Food and Drug Administration (FDA) has accepted Merck's New Drug Application (NDA) for doravirine islatravir, a novel combination therapy for HIV treatment. This approval marks a significant milestone in Merck's HIV clinical development pipeline, following the presentation of new data at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda [1].Merck's doravirine islatravir combination is a once-weekly oral regimen designed to treat adults with HIV-1 infection. The therapy aims to simplify HIV treatment by reducing the frequency of dosing, potentially improving patient adherence and quality of life. The FDA's acceptance of the NDA is based on the positive results from two Phase 1 and one Phase 2b clinical trials, which demonstrated the safety and tolerability of the drug combination [1].
The data presented at IAS 2025 included findings from a Phase 2b dose-ranging study that evaluated a higher dose of islatravir (20mg) and three doses of ulonivirine in treatment-naive adults living with HIV-1. These trials also assessed the safety and tolerability of weekly dosing of ulonivirine and drug interactions between islatravir and ulonivirine [1].
Merck has been actively developing this combination therapy, with the goal of providing an effective and convenient treatment option for HIV patients. The company has been conducting extensive research on the pharmacokinetics and safety profiles of doravirine and islatravir, with a focus on minimizing side effects and improving patient outcomes.
The FDA's acceptance of the NDA is a significant step forward in the fight against HIV. It is expected that doravirine islatravir will become available in the market soon, providing healthcare providers with a new tool to manage HIV infections more effectively.
References:
[1] https://www.marketscreener.com/quote/stock/MERCK-CO-INC-13611/news/Merck-to-Present-New-Data-Highlighting-Research-Advancements-Across-its-HIV-Prevention-and-Treatment-50457482/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet